Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England

Annabel A Powell; Linda Power; Samantha Westrop; Kelsey McOwat; Helen Campbell; Ruth Simmons; Mary E Ramsay; Kevin Brown; Shamez N Ladhani; Gayatri Amirthalingam

doi:10.2807/1560-7917.ES.2021.26.28.2100634

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England

Euro Surveill. 2021 Jul;26(28):2100634. doi: 10.2807/1560-7917.ES.2021.26.28.2100634.

Authors

Affiliations

¹ Immunisation and Countermeasures Division, Public Health England, London, United Kingdom.
² London School of Hygiene and Tropical Medicine, London, United Kingdom.
³ Paediatric Infectious Diseases Research Group, St. George's University of London, London, United Kingdom.

PMID: 34269172
PMCID: PMC8284043
DOI: 10.2807/1560-7917.ES.2021.26.28.2100634

Abstract

Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5-98.1 vs 48% (41.0-57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5-98.2 vs 75.0% (57.8-87.9).

Keywords: BNT162b2; COVID-19 vaccine; ChAdOx1/nCoV-19; Comirnaty; Reactogenicity; Vaxevria; heterologous schedule; prime-boost.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
COVID-19 Vaccines*
COVID-19*
England / epidemiology
Female
Humans
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines